I

Intercept Pharmaceuticals Inc
F:I4P

Watchlist Manager
Intercept Pharmaceuticals Inc
F:I4P
Watchlist
Price: 17.52 EUR Market Closed
Market Cap: 732.8m EUR
Have any thoughts about
Intercept Pharmaceuticals Inc?
Write Note

Intercept Pharmaceuticals Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intercept Pharmaceuticals Inc
Net Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
I
Intercept Pharmaceuticals Inc
F:I4P
Net Income
-$61.6m
CAGR 3-Years
42%
CAGR 5-Years
29%
CAGR 10-Years
3%
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$489.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%

See Also

What is Intercept Pharmaceuticals Inc's Net Income?
Net Income
-61.6m USD

Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Net Income amounts to -61.6m USD.

What is Intercept Pharmaceuticals Inc's Net Income growth rate?
Net Income CAGR 10Y
3%

The average annual Net Income growth rates for Intercept Pharmaceuticals Inc have been 42% over the past three years , 29% over the past five years , and 3% over the past ten years .

Back to Top